PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA - Sebastian Grosicki; Su-Peng Yeh; Shang-Yi Huang; Ja Min Byun; Christine Dirienzo; Andrea Viqueira (HemaSphere, 2023)